Compare WYETH LTD with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs DR. REDDYS LAB - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD DR. REDDYS LAB WYETH LTD/
DR. REDDYS LAB
 
P/E (TTM) x 27.7 22.3 124.1% View Chart
P/BV x 5.3 3.3 160.1% View Chart
Dividend Yield % 1.3 0.7 180.2%  

Financials

 WYETH LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    WYETH LTD
Mar-13
DR. REDDYS LAB
Mar-19
WYETH LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,0442,875 36.3%   
Low Rs8181,888 43.3%   
Sales per share (Unadj.) Rs298.6930.2 32.1%  
Earnings per share (Unadj.) Rs57.2117.4 48.7%  
Cash flow per share (Unadj.) Rs58.4185.8 31.4%  
Dividends per share (Unadj.) Rs17.0020.00 85.0%  
Dividend yield (eoy) %1.80.8 217.4%  
Book value per share (Unadj.) Rs249.5844.4 29.5%  
Shares outstanding (eoy) m22.72166.07 13.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.6 121.8%   
Avg P/E ratio x16.320.3 80.2%  
P/CF ratio (eoy) x15.912.8 124.3%  
Price / Book Value ratio x3.72.8 132.4%  
Dividend payout %29.717.0 174.4%   
Avg Mkt Cap Rs m21,157395,496 5.3%   
No. of employees `0000.522.0 2.2%   
Total wages/salary Rs m40033,562 1.2%   
Avg. sales/employee Rs Th13,787.47,032.8 196.0%   
Avg. wages/employee Rs Th813.01,527.9 53.2%   
Avg. net profit/employee Rs Th2,643.3887.7 297.8%   
INCOME DATA
Net Sales Rs m6,783154,482 4.4%  
Other income Rs m3533,375 10.4%   
Total revenues Rs m7,136157,857 4.5%   
Gross profit Rs m1,61731,782 5.1%  
Depreciation Rs m2711,348 0.2%   
Interest Rs m6889 0.6%   
Profit before tax Rs m1,93822,920 8.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6323,858 16.4%   
Profit after tax Rs m1,30119,500 6.7%  
Gross profit margin %23.820.6 115.9%  
Effective tax rate %32.616.8 193.8%   
Net profit margin %19.212.6 151.9%  
BALANCE SHEET DATA
Current assets Rs m6,984111,101 6.3%   
Current liabilities Rs m2,05658,973 3.5%   
Net working cap to sales %72.633.7 215.3%  
Current ratio x3.41.9 180.3%  
Inventory Days Days9979 125.1%  
Debtors Days Days2494 25.4%  
Net fixed assets Rs m244101,245 0.2%   
Share capital Rs m227830 27.4%   
"Free" reserves Rs m5,441139,406 3.9%   
Net worth Rs m5,668140,236 4.0%   
Long term debt Rs m2522,000 0.1%   
Total assets Rs m7,901224,656 3.5%  
Interest coverage x353.326.8 1,319.3%   
Debt to equity ratio x00.2 2.8%  
Sales to assets ratio x0.90.7 124.9%   
Return on assets %16.59.1 182.1%  
Return on equity %22.913.9 165.0%  
Return on capital %34.014.9 227.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1588,673 0.0%   
Fx outflow Rs m2,67719,104 14.0%   
Net fx Rs m-2,66269,569 -3.8%   
CASH FLOW
From Operations Rs m92328,704 3.2%  
From Investments Rs m317-7,727 -4.1%  
From Financial Activity Rs m-481-21,326 2.3%  
Net Cashflow Rs m759-314 -241.8%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 5.4 209.3%  
FIIs % 7.2 35.3 20.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 30.4 15.3 198.7%  
Shareholders   21,978 75,885 29.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   SHASUN PHARMA  CIPLA  TORRENT PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - CADILA HEALTHCARE COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS